Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients

Mediators of Inflammation

Volumn 2005, Issue 3, 2005, Pages 144-149

  Dziankowska Bartkowiak, Bozena ^a   Waszczykowska, Elzbieta ^a   Zalewska, Anna ^a   Sysa Jȩdrzejowska, Anna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOSTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFUSE SCLERODERMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART MUSCLE FIBROSIS; HUMAN; LIMITED SCLERODERMA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASES; ENDOSTATINS; FEMALE; FIBROSIS; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; STATISTICS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 25644436232     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/MI.2005.144     Document Type: Article

References (36)

1. Goetz RH. Pathology of progressive systemic sclerosis with special reference to changes in the viscera. Clin Proc (S Africa). 1945;4:337-342.
2. Stone JH, Wigley FM. Management of systemic sclerosis: the art and science. Semin Cutan Med Surg. 1998;17(1):55-64.
3. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43(11):2437-2444.
4. Black CM. The aetiopathogenesis of systemic sclerosis. J Intern Med. 1993;234(1):3-8.
5. Josko J, Gwozdz B, Jedrzejowska-Szypulka H, Hendryk S. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit. 2000;6(5):1047-1052.
6. Pepper MS. Manipulating angiogenesis. From basic science to the bedside. Arterioscler Thromb Vasc Biol. 1997;17(4):605-619.
7. Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE. Evidence of IL-18 as a novel angiogenic mediator. J Immunol. 2001;167(3):1644-1653.
8. Kaminski MJ, Majewski S, Jablonska S, Pawinska M. Lowered angiogeneic capability of peripheral blood lymphocytes in progressive systemic sclerosis (scleroderma). J Invest Dermatol. 1984;82(3):239-243.
9. Koch AE, Litvak MA, Burrows JC, Polverini PJ. Decreased monocyte-mediated angiogenesis in scleroderma. Clin Immunol Immunopathol. 1992;64(2):153-160.
10. Yazawa N, Kikuchi K, Ihn H, et al. Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis. J Am Acad Dermatol. 2000;42(pt 1):70-75.
11. Saarialho-Kere U, Kerkela E, Jahkola T, Suomela S, Keski-Oja J, Lohi J. Epilysin (MMP-28) expression is associated with cell proliferation during epithelial repair. J Invest Dermatol. 2002;119(1):14-21.
12. Fini ME, Cook JR, Mohan R, Brinckerhoff CE. Regulation of matrix metalloproteinase gene expression. In: Parks WC, Mecham, RP, eds. Matrix Metalloproteinases. New York, NY: Academic Press; 1998:299-356.
13. Bogaczewicz J, Chodorowska G, Krasowoska D. Role of matrix metalloproteinases and their tissue inhibitors in scleroderma [in Polish]. Przegl Dermatol. 2003;5:373-381.
14. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem. 1996;271(48):30375-30380.
15. Wynn J, Fineberg N, Matzer L, et al. Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. Am Heart J. 1985;110(pt 1):123-127.
16. Follansbee WP. Organ involvement: cardiac. In: Clements PJ, Furst DE, eds. Systemic Sclerosis. Baltimore, Md: Wiliams & Wilkins; 1996:333-364.
17. Valentini G, Maione S. Cardiopathy in systemic sclerosis. Recenti Prog Med. 1996;87(11):557-563.
18. Mitchell H, Bolster MB, LeRoy EC. Scleroderma and related conditions. Med Clin North Am. 1997;81(1):129-149.
19. Kucharz EJ. Heart lesions in patients with systemic sclerosis [in Polish]. Pol Arch Med Wewn. 1997;97(1):1-6.
20. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46(3):428-440.
21. Wranicz K, Zielinska M, Cygankiewicz I, Dziankowska-Bartkowiak B, Sysa-Jedrzejowska A. Early cardiovascular involvement in patients with systemic sclerosis (SSc). Med Sci Monit. 2002;8(2):CR78-82.
22. Zabinska-Plazak E, Wojas-Pelc A, Plazak W, Bogdaszewska-Czabanowska J, Tracz W. Heart rhythm disturbances and variability of heart rhythm in scleroderma patients [in Polish]. Przegl Dermatol. 2003;4:251-258.
23. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23(5):581-590.
24. Kahaleh MB. Soluble immunologic products in scleroderma sera. Clin Immunol Immunopathol. 1991;58(1):139-144.
25. Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore). 1980;59(6):393-408.
26. Sasaki T, Fukai N, Mann K, Gohring W, Olsen BR, Timpl R. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J. 1998;17(15):4249-4256.
27. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277-285.
28. Kim YM, Jang JW, Lee OH, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 2000;60(19):5410-5413.
29. Dixelius J, Larsson H, Sasaki T, et al. Endostatininduced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood. 2000;95(11):3403-3411.
30. Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum. 2000;43(4):889-893.
31. Halfter W, Dong S, Schurer B, Cole GJ. Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem. 1998;273(39):25404-25412.
32. Distler O, Del Rosso A, Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res. 2002;4(6):R11.
33. Mattila L, Airola K, Ahonen M, et al. Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. J Invest Dermatol. 1998;110(4):416-421.
34. Yazawa N, Kikuchi K, Ihn H, Fujimoto M, Kubo M, Tamaki T. Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis. J Am Acad Dermatol. 2000;42(pt 1):70-75.
35. Manabe J, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res. 2002;91:1103-1113.
36. Szary J, Szala S. Endostatin in neoplasm therapy [in Polish]. Nowotwory J Oncol. 2002;52:159-164.